Cellceutix Corp (OTCMKTS:CTIX)
Cellceutix Corp (OTCMKTS:CTIX) has completed patient enrollment in its third and final Phase 3 open-label clinical trial for Brilacidin. The non-corticosteroid, non-biologic treatment is being developed as a novel treatment for mild-to-moderate Ulcerative Proctitis / Ulcerative Proctosigmoiditis (UP/UPS) – conditions which strike over 1 million Americans per year.
Brilacidin Trial Overview
Cellceutix Corp (OTCMKTS:CTIX) says it enrolled 17 patients who will receive Brilacidin as part of a six-week treatment. Cohort A and Cohort B, each made up of 6 patients, have already completed treatment having received 50mg and 100mg each. Cohort C is the one that is still in progress; made up of 5 patients each receiving, daily, 200mg of the candidate drug.
The primary endpoint of the trial is determining clinical remission at day 42 while using Modified Mayo Disease Activity Index (MMDAI). Secondary efficacy endpoint, on the other hand, includes change in MMDAI score as well as a change patient’s quality of life.
Previous trials have generated positive results. Enrolled patients have responded well to the treatment and demonstrated shown strong signs of the drug’s efficacy. This all but confirms Brilacidin credentials as a novel treatment of the two types of Inflammatory Bowel Disease.
“We expect that a complete body of data and evidence, including importantly endoscopic evaluation, will demonstrate just how safe and effective Brilacidin, as an emerging treatment, might one day become for those suffering from a wide range of debilitating inflammatory bowel conditions,” said Chief Medical Officer, Arthur P. Bertolino.
In addition to the ongoing Brilacidin trial, Cellceutix Corp (OTCMKTS:CTIX) is also carrying out trials on its first-in-class drug candidates that include Prurisol and Kevetrin. Given that each drug is pushing into a major market explains why the stock has been on an impressive run in the recent past.
Prurisol is currently in a Phase 2 trial and, if successful, will expand the company’s footprint into the psoriasis market. Data on the ongoing trial is set to be released sometime in the third quarter of this year. Kevetrin, on the other hand, is a drug that the company is developing for the treatment of ovarian cancer. Its Phase 2a trial of the drug is set to be completed at the end of the second quarter.
Cellceutix Corp (OTCMKTS:CTIX) is currently trading at a tight range of between $0.89 a and $1.03 a share after having rallied to highs of $ 1.07 a share in recent weeks. The stock shed 5.9% in market value to end the week at $0.960 a share.
I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.
About the author: Mario grew up in Phoenix, AZ and attended college on a fencing scholarship. After college he went to work for a nationally recognized investment analysis website located in Chicago. For extra money, Mario writes, using a pseudonym, about nano-cap companies with high-growth potentials.